

AWARD NUMBER: W81XWH-14-1-0041

TITLE: Targeting Extracellular Matrix Glycoproteins in Metastases for Tumor-Initiating Cell Therapy

PRINCIPAL INVESTIGATOR: Ho-Lun Wong

CONTRACTING ORGANIZATION: Temple University
Philadelphia, PA 19122

REPORT DATE: April 2016

TYPE OF REPORT: Final report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE April 2016		2. REPORT TYPE Final Report		3. DATES COVERED 23 Jan 2014 - 22 Jan 2016	
4. TITLE AND SUBTITLE Targeting Extracellular Matrix Glycoproteins in Metastases for Tumor-Initiating Cell Therapy				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-14-1-0041	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Ho-LUN WONG E-Mail: ho-lun.wong@temple.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) TEMPLE UNIVERSITY-OF THE COMMONWEALTH SY KENNETH GELLER, PHD1801 N BROAD STPHILADELPHIA PA				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The proposed research is a proof-of-concept study that focuses on testing a new cancer targeting strategy that aims at enhancing nanodelivery of drugs to osteopontin (OPN) that are often overexpressed in advanced prostate cancer cells and their microenvironment. To evaluate this strategy, lipid-based nanocarrier that targets OPN (i.e. OPN-LN) was developed, characterized and compared with non-targeting LN. This OPN-LN was used as the key platform to study the OPN targeting strategy. In the reporting period, OPN-LN was prepared by conjugation of OPN antibody onto the surface of lipid nanocarriers using SATA as the conjugation reagent. Our data show that the OPN-LN have good dispersion stability (no noticeable aggregation at 37 °C in 2 days) and regular morphology. When compared with non-targeting LN, OPN-LN were more efficiently taken up by PC-3M prostate cancer cells which were shown to be OPN expressing as indicated by Western blotting analysis. No significant increase in non-specific toxicity was observed after OPN antibody conjugation. In brief, OPN targeting apparently can improve the nanodelivery to OPN expressing prostate cancer cells. The impact on anticancer efficacy will be evaluated in the next reporting period.					
15. SUBJECT TERMS Osteopontin, prostate cancer, targeted delivery, nanomedicine					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	17	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	2
2. Keywords.....	2
3. Accomplishments.....	3
4. Impact.....	12
5. Changes/Problems.....	13
6. Products.....	14
7. Participants & Other Collaborating Organizations.....	15
8. Special Reporting Requirements.....	17
9. Appendices.....	17

1. **INTRODUCTION:**

The proposed research is a proof-of-concept study that focuses on testing a new cancer targeting strategy that aims at enhancing nanodelivery of drugs to the glycoproteins (e.g. osteopontin, OPN) that are often overexpressed in advanced prostate cancer cells and their microenvironment. The purpose is to establish this novel delivery strategy for effective and safe prostate cancer therapy. To evaluate this strategy, in the first stage, it was proposed that a nanocarrier that targets OPN will be developed and characterized, and this nanocarrier will be used for determining the feasibility of the proposed OPN-targeting strategy (i.e. Aim #1 – To determine the feasibility of OPN-targeted strategy for enhancing nanomedicine delivery to OPN-rich targets). In the second stage, this OPN-targeting nanocarrier will be loaded with an anticancer drug and the in vitro therapeutic activities against prostate cancer cells with TIC behaviors will be studied (i.e. Aim #2 – To study the therapeutic effects of OPN-targeted delivery on metastatic prostate cancer).

In general, the tasks listed under both aims are completed. A manuscript is being prepared and is close to getting submitted pending some final polishing. This is the FINAL report for this award.

2. **KEYWORDS:**

Osteopontin, prostate cancer, targeted delivery, nanomedicine

3. **ACCOMPLISHMENTS:**

▪ **What were the major goals of the project?**

Specific Aim 1: To determine the feasibility of OPN-targeting strategy for enhancing nanomedicine delivery to OPN-rich targets.

- Objective 1: Prepare and characterize OPN-targeting carrier (month 1-6) (completed in 12 months)
- Objective 2: Evaluate the effect of decorating a nanocarrier with OPN-targeting moieties on OPN-binding (month 1-6) (completed in 12 months)
- Objective 3: Evaluate the effect of OPN-targeting on nanomedicine delivery to cell culture (month 4-9) (completed in 12 months)

Specific Aim 2 To study the therapeutic effects of OPN-targeted delivery on metastatic prostate cancer

- objective 1: Preparation of prostaspheres (month 1-6) (not completed)
- objective 2: Evaluate the therapeutic effects of OPN-targeting system carrying a hedgehog pathway inhibitor (month 3-12) (not completed)

▪ **What was accomplished under these goals?**

Major activities and specific objectives: In the funding period, we focused on completing the objectives of both Aims as listed in the SOW including

1. Aim 1:

- objective 1: Prepare and characterize OPN-targeting carrier
- objective 2: Evaluate the effect of decorating a nanocarrier with OPN-targeting moieties on OPN-binding
- objective 3: Evaluate the effect of OPN-targeting on nanomedicine delivery to cell culture

2. Aim 2:

- objective 1: Preparation of prostaspheres

- objective 2: Evaluate the therapeutic effects of OPN-targeting system carrying a hedgehog pathway inhibitor

Significant results: The more significant results are summarized as below

1. **Specific Aim 1:** To determine the feasibility of OPN-targeting strategy for enhancing nanomedicine delivery to OPN-rich targets.

a. Preparation of Osteopontin(OPN)-targeting carrier (under Objective 1). Lipid nanoparticles were prepared using a blend of biocompatible lipids and phospholipids such as triglyceride, triolein, DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), and/or PEG-DSPE (Polyethylene glycol-distearoyl-glycero-phosphoethanolamine). These nanoparticles were conjugated with OPN-antibody using SATA as conjugation agent. The OPN-targeting lipid nanoparticles (OPN-LN) showed no visible aggregation and precipitation at 37 °C in 72 hours. OPN-LN were further characterized and the results are shown as below.


b. Dynamic light scattering: Size, PDI, zeta potential (under Objective 1). The average size, polydispersity (PDI) of size and zeta potentials of LN before and after conjugation with OPN-antibody are measured using dynamic light scattering technique (Zetasizer, Malvern, UK) and shown below. In addition, in preparation of the works under Specific Aim 2 we also attempted to encapsulate a hedgehog pathway inhibitor cyclopamine (CP), and the data are as follows:

	Average diameter (nm)	PDI	Zeta potential (mV)
Blank LN, no OPN-antibody	149.4	0.196	-20.0
Blank LN, +OPN-antibody coating	154.3	0.174	-18.2
LN-loading CP, no OPN-antibody	161.7	0.181	-28.7
LN-loading CP, +OPN-antibody	169.8	0.198	-25.9

The data indicate that conjugation of OPN-antibody onto LN and encapsulation of CP drug did not significantly increase the average size of the nanocarriers (some modest increases were observed but not statistically significant). The PDI value reflects the distribution of

nanocarrier size. PDI values <0.3 in all samples suggest that the conjugation also did not lead to the formation of some excessively large particulate matters. The modestly negative zeta potentials as shown in the table help to maintain the dispersed state of OPN-LN. In general, OPN-antibody conjugation and loading of drug do not have any detrimental impact on the size/charge aspect of the lipid nanocarriers.

c. Dispersion stability study (under Objective 1). To rule out the possibility OPN-LN forming aggregates that may affect their interaction with the target cells, their size at different conditions (4 °C or 37 °C, up to 5 days) was monitored using dynamic light scattering. The results are summarized as below:




It is shown that OPN-LN remained similar in size even at 37 °C for 2 days. Some increase in size suggesting modest aggregation occurred after 5 days of incubation. In general, the OPN-LN can be considered fairly resistant to aggregation and this should not be a major factor affecting the cell-nanocarrier interaction.

d. Characteristics of OPN-targeting nanoparticles (OPN-LP) delivering GDC-0449 (i.e. Vismodegib) (Objective 1). Later, as we recognized that more specific, potent hedgehog inhibitors are available, we decided to prepare OPN-LN using the new generation drugs. GDC-0449 (brand name Vismodegib) was chosen because it represents the first hedgehog signaling pathway that has gained the approval of FDA. Comparing to cyclopamine, Vismodegib is more

potent (literature IC₅₀ value of cyclopamine is more than 10-fold higher) and selective on sonic hedgehog pathway. The potential side effects will be lower using this newer drug.

The resulting Vismodegib-OPN-LN (Vis-OPN-LN) has diameter at 118 +/- 18 nm (mean +/- SD; n=4, See Figure 1) with uniform size (polydispersity index averages 0.178 +/- 0.041). Drug encapsulation efficiency was 72.4 +/- 4.6%. The nanoformulation showed no significant size growth, aggregation and precipitation at 37 °C in 72 hours, indicating good physical stability under the conditions used for the cell culture experiments.

e. Electron microscopy (EM) (under Objective 1): To double-check the size data from dynamic light scattering and learn the morphology of OPN-LN, transmission electron microscopy imaging was performed. A representative image is shown as follows:



OPN-LN was shown to be spherical and regular in morphology. The size is consistent with the dynamic light scattering measurement.

f. OPN-antibody conjugation (under Objective 1). OPN-LN was prepared with different antibody to LN ratios. ELISA was performed to evaluate the amount of unconjugated, free antibody and the result obtained was used to determine the efficiency of antibody conjugation (amount of antibody conjugated x 100%/ amount of antibody added). The result shows a conjugation efficiency of the nanoformulation at over 30%.

g. Confirmation of OPN expression in prostate cancer cells (Objective 2): To determine the OPN expression levels in different human prostate cancer cell lines, Western blotting analysis


was performed using anti-human OPN mouse IgG as primary antibody and goat anti-mouse IgG-HRP as secondary antibody.



OPN was expressed in all four prostate cancer cells tested (From left to right: PC-3M, Du145, LNCap, PC3). The strongest OPN expression was observed in PC-3M. PC-3M is a metastatic subline of PC3 prostate epithelial cancer cells. Because of its high expression it was chosen as the primary cell line for subsequent *in vitro* studies.

h. Evaluate interaction of OPN-LN and OPN-expressing prostate cancer cells (Objective 2):

To study the correlation between OPN-antibody conjugation and interaction with the OPN expressing prostate cancer cells, fluorescent microscope imaging was performed. PC-3M cells were used and LN were labeled with FITC-conjugated DSPC-PEG. Representative images are shown below (from left to right: non-targeting LN, OPN-LN with low density of OPN antibody, OPN-LN with high density of OPN antibody).




The cellular uptake of LN noticeably improved with surface decoration OPN-antibodies on the LN. This demonstrates the feasibility of using OPN-targeting for improved nanoparticle-cell interaction.

i. Evaluate baseline cell toxicity of OPN-LN (Objective 3): Sometimes active targeting can render a nanocarrier inherently more toxic to cells (even without drug). This may not necessarily be beneficial as the toxicity derived from the nanocarrier device itself is often less disease specific and may affect the non-target cells. We performed MTT viability assay using prostate cells with low OPN expression level (PC3). There is no significant difference between the viabilities of PC3 cells treated with OPN-LN, non-targeting LN and vehicle control (all without

any drug encapsulated). The data indicate that OPN-antibody conjugation did not affect the baseline toxicity of the nanocarrier.

2. Specific Aim 2. To study the therapeutic effects of OPN-targeted delivery on metastatic prostate cancer


a. Preparation of prostaspheres. Formation of cell spheres from individual cells indicates that these cells have tumor-initiating potential. Prostraspheres formed from individual PC-3M cells were prepared (See Figure below, left panel). Prostraspheres generally formed approximately 10-14 days after initiation, and the resulting prostaspheres were stable (no sign of spontaneous disintegration) over the course of 7 more days without drug treatment (Fig., right).



Prostasphere of PC-3M cells. Left: Microscope image of prostasphere. Cell nuclei stained for visualization. Right: Number of prostaspheres remained intact for extended culture (started with 10 prostaspheres on day 0, 3 experiments).


b. Effect on formation of prostaspheres. Successful suppression of prostasphere formation is an indication that the treatment may have potential activity to suppress renewal of tumor-initiating cells to form micrometastases. We evaluated the effect of different treatments on formation of prostaspheres from individual PC-3M cells. Treatments including free Vismodegib, blank OPN-LN and Vis-OPN-LN were compared. Cells were seeded and treated for 3 days, and then allowed to form prostaspheres. Fig. 3 shows that without treatment (at 0), around 7.5% cells eventually formed prostaspheres. Blank OPN-LN did not have significant effect except at the highest concentration tested. Vis-OPN-LN was similarly effective to free drug in suppressing the prostasphere formation at high levels (100 μ M or above) and was significantly more effective at

lower concentrations. The data indicate that Vis-OPN-LN is comparable or even modestly better than the free drug in suppressing the repopulation of prostate cancer cells. It should be noted that this is an *in vitro* result. In *in vivo* data with the passive and active tumor targeting properties the local drug concentration in the tumor when delivered by Vis-OPN-LN should likely be higher than the free drug. This issue will be addressed in future *in vivo* studies.



Effect of Vismodegib nanoparticles on formation of PC-3M prostatespheres.


c. Effect on existing prostatespheres. We also evaluated the effect of the treatments on existing prostatespheres. They were treated with free drug or Vis-OPN-LN for 5 days, and the prostatespheres were trypsinized and MTT assay was performed. Results are normalized and expressed as % of untreated control (Fig. 4). It can be seen that the nanoparticles were significantly more effective than the free drug in killing the cells in existing prostatespheres.



Effect of Vis-OPN-NP on PC-3M cells in prostaspheres. Each point represent means $\pm$ SD (3 independent experiments).

d. Pharmacodynamic effect of Vis-OPN-LN on Smo, MMP-2 and MMP-9. We attempted to evaluate the change in expression of the primary target of hedgehog inhibitors, i.e. Smo and other stromal factors that may be expressed in tumor microenvironment, e.g. MMP2 and MMP9, indicating tumor aggressiveness and invasiveness. Western blotting was performed, the bands were analyzed with ImageJ software (NIH freeware) and representative result is shown as below.

Vis-OPN-LN reduced the expression of Smo and MMP-2 to 43% and 48% of the blank control, respectively, and was modestly better than free drug (12% and 6% lower than Free Vis group). The effect on MMP9 is minimal. Overall Vis-OPN-LN demonstrated noticeable pharmacodynamics effects including Smo, the primary target of hedgehog inhibitor. At a minimum, its effects are at least comparable to the free drug.



Western immunoblotting result. Primary antibodies all rabbit origin, Smo: sc-13943, MMP2: sc-10736, MMP9: sc-2313, Secondary antibodies goat-anti-rabbit-IgG-HRP. All purchased from Santa Cruz. Primary antibody 1:500, Secondary antibody 1:2500).

Goals to be completed in coming reporting period:

Not applicable (this is the final report)

- **What opportunities for training and professional development has the project provided?**
Nothing to report
- **How were the results disseminated to communities of interest?**
Nothing to report
- **What do you plan to do during the next reporting period to accomplish the goals?**
Not applicable (this is the final report)

4. IMPACT:

- **What was the impact on the development of the principal discipline(s) of the project?**

Overall, the findings in the research funded by this exploratory grant have led to successful development of a novel lipid-based nanocarrier that can deliver hedgehog inhibitors (e.g. Vismodegib) with targeting properties to osteopontin, a protein that tends to express on advanced prostate cancer cells and their microenvironment. The resulting nanoformulations Vis-OPN-LN has good interaction with metastatic prostate cancer cells such as PC-3M which express high OPN level, and can both prevent prostaspheres from forming and kill the cells in existing prostaspheres. In other words, Vis-OPN-LN has the potential to target the cancer cells with tumorigenic potential, which has strong significance in cancer treatment as this cell subpopulation are probably the ones that lead to cancer cell repopulation after chemotherapy.

The finding in Western blotting, while demonstrating that the nanoformulations has good activity suppressing the key target (Smo) of the sonic hedgehog pathway, which plays a critical role in cancer metastasis and progression, the effects are still more modest than initially expected. The nanoformation probably still has room to improve. As the free Vismodegib has similar (and actually a bit weaker) effects, in the future studies we may consider a more potent hedgehog inhibitor. Regardless, this study has already demonstrated the feasibility of this new OPN-targeted nanotherapeutic strategy.

- **What was the impact on other disciplines?**

Nothing to report

- **What was the impact on technology transfer?**

Nothing to report

- **What was the impact on society beyond science and technology?**

Nothing to report

5. CHANGES/PROBLEMS:

- **Changes in approach and reasons for change**

No significant changes in the approach.

- **Actual or anticipated problems or delays and actions or plans to resolve them**

Nothing to report

- **Changes that had a significant impact on expenditures**

Nothing to report

- **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to report

- **Significant changes in use or care of human subjects**

Nothing to report

- **Significant changes in use or care of vertebrate animals**

Nothing to report

- **Significant changes in use of biohazards and/or select agents**

Nothing to report

6. PRODUCTS:

Publications, conference papers, and presentations

- Xue HY, Tran NT, Wong HL. Development of a nanodelivery system targeting glycoproteins expressed in advanced prostate cancer cells and their microenvironment. *AAPS Meeting 2015*, AM-15-1766, 2015.
- A manuscript is close to submission pending on some polishing.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS:

▪ What individuals have worked on the project?

Name:	Ho-Lun Wong
Project Role:	PI
Researcher Identifier ORCID ID:	0000-0002-0349-7708
Nearest person month worked:	12
Contribution to Project:	He designed the project, performed nanocarrier preparation and characterization, conducted some in vitro works, and is mainly responsible for data analysis and manuscript writing
Funding Support:	NIH 1R01CA168917
Name:	Jan Romano
Project Role:	Part time technician
Researcher Identifier (e.g. ORCID ID):	Not applicable
Nearest person month worked:	7
Contribution to Project:	Ms Romano has assisted Dr. Wong in nanoparticle preparation and characterization, and was responsible for cancer cell culture and also assisted in some in vitro experiments
Funding Support:	None
Name:	Ngoc Tran
Project Role:	Part time technician
Researcher Identifier (e.g. ORCID ID):	Not applicable
Nearest person month worked:	6
Contribution to Project:	Ms Tran followed up on the technical tasks after Ms. Romano left for a new job. She helped prepare the cell spheroids and assisted in the in vitro experiments
Funding Support:	None

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to report

- **What other organizations were involved as partners?**

Nothing to report

8. SPECIAL REPORTING REQUIREMENTS

Nothing to report

9. APPENDICES: Nothing to report